G1 Therapeutics, Inc. (NASDAQ:GTHX) is on recovery track with 34.71% gain from a 1-year low price of $15.21. The company added 2.91% to attain the price of $20.49 on 01/10/2019. Throughout the recent session, the prices were hovering between $19.01 and $20.67. These shares are 242.46% off its target price of $70.17 and the current market capitalization stands at $776.57M. The recent change has given its price a -37.42% deficit over SMA 50 and -70.55% deficit over its 52-week high. The stock witnessed -37.91% declines, -52.92% declines and -53.67% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found GTHX’s volatility during a week at 6.53% and during a month it has been found around 8.95%.G1 Therapeutics, Inc. (GTHX) Top Holders
Institutional investors currently hold around $528 million or 83.9% in GTHX stock. Look at its top three institutional owners. Fmr Llc owns $103.86 million in G1 Therapeutics, Inc., which represents roughly 13.37% of the company’s market cap and approximately 19.67% of the institutional ownership. Similar statistics are true for the second largest owner, Wellington Management Group Llp, which owns 3,209,187 shares of the stock are valued at $63.9 million. The third largest holder is Price T Rowe Associates Inc /Md/, which currently holds $38.65 million worth of this stock and that ownership represents nearly 4.98% of its market capitalization.G1 Therapeutics, Inc. 13F Filings
At the end of September reporting period, 81 institutional holders increased their position in G1 Therapeutics, Inc. (NASDAQ:GTHX) by some 4,240,112 shares, 34 decreased positions by 842,280 and 13 held positions by 21,431,892. That puts total institutional holdings at 26,514,284 shares, according to SEC filings. The stock grabbed 32 new institutional investments totaling 875,468 shares while 12 institutional investors sold out their entire positions totaling 189,019 shares.G1 Therapeutics, Inc. (NASDAQ:GTHX) Insider Trades
Multiple company employees have indulged in significant insider trading. G1 Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Schwalm Cynthia has acquired 1,420 shares of G1 Therapeutics, Inc. (GTHX) in trading session dated Dec. 26, 2018. These shares are worth $26,199 and were traded at $18.45 each. The SEC filing shows that Hanson James S. performed a purchase of 1,000 shares. The General Counsel added these shares by way of transaction on Dec. 26, 2018. The company’s shares were assimilated at $18.25 per share worth to an investment of some $18,250 on account of Hanson James S..
Ch. Medical Officer & SVP R&D, Malik Rajesh, sold 3,776 common shares of G1 Therapeutics, Inc. (GTHX) in the open market. In a transaction dated Dec. 17, 2018, the shares were put up for sale at an average price of $30, raking in a sum of $113,280. After this sale, 14,700 common shares of GTHX are directly owned by the insider, with total stake valued at $301,203.
In the transaction dated Dec. 10, 2018, the great number of shares acquired came courtesy the Chief Commercial Officer; Demaree John added a total of 1,000 shares at an average price of $33.15, amounting to approximately $33,150. The insider now directly owns 5,250 shares worth $107,573.G1 Therapeutics, Inc. (GTHX) Analyst Guide
Several analysts have released their opinion on G1 Therapeutics, Inc. (NASDAQ:GTHX), with 2 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.67 average brokerage recommendation.